Cargando…

Increase in Tumor Control and Normal Tissue Complication Probabilities in Advanced Head-and-Neck Cancer for Dose-Escalated Intensity-Modulated Photon and Proton Therapy

INTRODUCTION: Presently used radiochemotherapy regimens result in moderate local control rates for patients with advanced head-and-neck squamous cell carcinoma (HNSCC). Dose escalation (DE) may be an option to improve patient outcome, but may also increase the risk of toxicities in healthy tissue. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Jakobi, Annika, Lühr, Armin, Stützer, Kristin, Bandurska-Luque, Anna, Löck, Steffen, Krause, Mechthild, Baumann, Michael, Perrin, Rosalind, Richter, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4653282/
https://www.ncbi.nlm.nih.gov/pubmed/26636038
http://dx.doi.org/10.3389/fonc.2015.00256
_version_ 1782401877044887552
author Jakobi, Annika
Lühr, Armin
Stützer, Kristin
Bandurska-Luque, Anna
Löck, Steffen
Krause, Mechthild
Baumann, Michael
Perrin, Rosalind
Richter, Christian
author_facet Jakobi, Annika
Lühr, Armin
Stützer, Kristin
Bandurska-Luque, Anna
Löck, Steffen
Krause, Mechthild
Baumann, Michael
Perrin, Rosalind
Richter, Christian
author_sort Jakobi, Annika
collection PubMed
description INTRODUCTION: Presently used radiochemotherapy regimens result in moderate local control rates for patients with advanced head-and-neck squamous cell carcinoma (HNSCC). Dose escalation (DE) may be an option to improve patient outcome, but may also increase the risk of toxicities in healthy tissue. The presented treatment planning study evaluated the feasibility of two DE levels for advanced HNSCC patients, planned with either intensity-modulated photon therapy (IMXT) or proton therapy (IMPT). MATERIALS AND METHODS: For 45 HNSCC patients, IMXT and IMPT treatment plans were created including DE via a simultaneous integrated boost (SIB) in the high-risk volume, while maintaining standard fractionation with 2 Gy per fraction in the remaining target volume. Two DE levels for the SIB were compared: 2.3 and 2.6 Gy. Treatment plan evaluation included assessment of tumor control probabilities (TCP) and normal tissue complication probabilities (NTCP). RESULTS: An increase of approximately 10% in TCP was estimated between the DE levels. A pronounced high-dose rim surrounding the SIB volume was identified in IMXT treatment. Compared to IMPT, this extra dose slightly increased the TCP values and to a larger extent the NTCP values. For both modalities, the higher DE level led only to a small increase in NTCP values (mean differences <2%) in all models, except for the risk of aspiration, which increased on average by 8 and 6% with IMXT and IMPT, respectively, but showed a considerable patient dependence. CONCLUSION: Both DE levels appear applicable to patients with IMXT and IMPT since all calculated NTCP values, except for one, increased only little for the higher DE level. The estimated TCP increase is of relevant magnitude. The higher DE schedule needs to be investigated carefully in the setting of a prospective clinical trial, especially regarding toxicities caused by high local doses that lack a sound dose–response description, e.g., ulcers.
format Online
Article
Text
id pubmed-4653282
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-46532822015-12-03 Increase in Tumor Control and Normal Tissue Complication Probabilities in Advanced Head-and-Neck Cancer for Dose-Escalated Intensity-Modulated Photon and Proton Therapy Jakobi, Annika Lühr, Armin Stützer, Kristin Bandurska-Luque, Anna Löck, Steffen Krause, Mechthild Baumann, Michael Perrin, Rosalind Richter, Christian Front Oncol Oncology INTRODUCTION: Presently used radiochemotherapy regimens result in moderate local control rates for patients with advanced head-and-neck squamous cell carcinoma (HNSCC). Dose escalation (DE) may be an option to improve patient outcome, but may also increase the risk of toxicities in healthy tissue. The presented treatment planning study evaluated the feasibility of two DE levels for advanced HNSCC patients, planned with either intensity-modulated photon therapy (IMXT) or proton therapy (IMPT). MATERIALS AND METHODS: For 45 HNSCC patients, IMXT and IMPT treatment plans were created including DE via a simultaneous integrated boost (SIB) in the high-risk volume, while maintaining standard fractionation with 2 Gy per fraction in the remaining target volume. Two DE levels for the SIB were compared: 2.3 and 2.6 Gy. Treatment plan evaluation included assessment of tumor control probabilities (TCP) and normal tissue complication probabilities (NTCP). RESULTS: An increase of approximately 10% in TCP was estimated between the DE levels. A pronounced high-dose rim surrounding the SIB volume was identified in IMXT treatment. Compared to IMPT, this extra dose slightly increased the TCP values and to a larger extent the NTCP values. For both modalities, the higher DE level led only to a small increase in NTCP values (mean differences <2%) in all models, except for the risk of aspiration, which increased on average by 8 and 6% with IMXT and IMPT, respectively, but showed a considerable patient dependence. CONCLUSION: Both DE levels appear applicable to patients with IMXT and IMPT since all calculated NTCP values, except for one, increased only little for the higher DE level. The estimated TCP increase is of relevant magnitude. The higher DE schedule needs to be investigated carefully in the setting of a prospective clinical trial, especially regarding toxicities caused by high local doses that lack a sound dose–response description, e.g., ulcers. Frontiers Media S.A. 2015-11-20 /pmc/articles/PMC4653282/ /pubmed/26636038 http://dx.doi.org/10.3389/fonc.2015.00256 Text en Copyright © 2015 Jakobi, Lühr, Stützer, Bandurska-Luque, Löck, Krause, Baumann, Perrin and Richter. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Jakobi, Annika
Lühr, Armin
Stützer, Kristin
Bandurska-Luque, Anna
Löck, Steffen
Krause, Mechthild
Baumann, Michael
Perrin, Rosalind
Richter, Christian
Increase in Tumor Control and Normal Tissue Complication Probabilities in Advanced Head-and-Neck Cancer for Dose-Escalated Intensity-Modulated Photon and Proton Therapy
title Increase in Tumor Control and Normal Tissue Complication Probabilities in Advanced Head-and-Neck Cancer for Dose-Escalated Intensity-Modulated Photon and Proton Therapy
title_full Increase in Tumor Control and Normal Tissue Complication Probabilities in Advanced Head-and-Neck Cancer for Dose-Escalated Intensity-Modulated Photon and Proton Therapy
title_fullStr Increase in Tumor Control and Normal Tissue Complication Probabilities in Advanced Head-and-Neck Cancer for Dose-Escalated Intensity-Modulated Photon and Proton Therapy
title_full_unstemmed Increase in Tumor Control and Normal Tissue Complication Probabilities in Advanced Head-and-Neck Cancer for Dose-Escalated Intensity-Modulated Photon and Proton Therapy
title_short Increase in Tumor Control and Normal Tissue Complication Probabilities in Advanced Head-and-Neck Cancer for Dose-Escalated Intensity-Modulated Photon and Proton Therapy
title_sort increase in tumor control and normal tissue complication probabilities in advanced head-and-neck cancer for dose-escalated intensity-modulated photon and proton therapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4653282/
https://www.ncbi.nlm.nih.gov/pubmed/26636038
http://dx.doi.org/10.3389/fonc.2015.00256
work_keys_str_mv AT jakobiannika increaseintumorcontrolandnormaltissuecomplicationprobabilitiesinadvancedheadandneckcancerfordoseescalatedintensitymodulatedphotonandprotontherapy
AT luhrarmin increaseintumorcontrolandnormaltissuecomplicationprobabilitiesinadvancedheadandneckcancerfordoseescalatedintensitymodulatedphotonandprotontherapy
AT stutzerkristin increaseintumorcontrolandnormaltissuecomplicationprobabilitiesinadvancedheadandneckcancerfordoseescalatedintensitymodulatedphotonandprotontherapy
AT bandurskaluqueanna increaseintumorcontrolandnormaltissuecomplicationprobabilitiesinadvancedheadandneckcancerfordoseescalatedintensitymodulatedphotonandprotontherapy
AT locksteffen increaseintumorcontrolandnormaltissuecomplicationprobabilitiesinadvancedheadandneckcancerfordoseescalatedintensitymodulatedphotonandprotontherapy
AT krausemechthild increaseintumorcontrolandnormaltissuecomplicationprobabilitiesinadvancedheadandneckcancerfordoseescalatedintensitymodulatedphotonandprotontherapy
AT baumannmichael increaseintumorcontrolandnormaltissuecomplicationprobabilitiesinadvancedheadandneckcancerfordoseescalatedintensitymodulatedphotonandprotontherapy
AT perrinrosalind increaseintumorcontrolandnormaltissuecomplicationprobabilitiesinadvancedheadandneckcancerfordoseescalatedintensitymodulatedphotonandprotontherapy
AT richterchristian increaseintumorcontrolandnormaltissuecomplicationprobabilitiesinadvancedheadandneckcancerfordoseescalatedintensitymodulatedphotonandprotontherapy